Restoring Skin Pigmentation with Product Overview Single-use medical device to perform autologous cell transfer (MKTP) Non-cultured epidermal cell suspension obtained by enzymatic digestion of a patient’s skin biopsy and applied with hyaluronic acid Surgeons and dermatologists treating patients with stable vitiligo, showing no progression of lesions and no new lesions for a minimum of 6 months Quick & Effective Ready for application in just 30 minutes, total procedure 60 to 120 min Good tolerance Uses patient’s own skin cells for a better tolerated and long-lasting solution Enhanced Stability Hyaluronic acid prevents cell dispersion, improving treatment outcomes Safe, CE-marked Ready-to-use solution, safe, proven in a multi-centric randomized study (1) Treatment outline & benefits (Michel Pascal,Mahsa GHASEMI,Rasta GHASEMI,Khaled Ezzedine (IPCC2014-ABS-1409) Healthy split skin biopsy 10cm2 or 1/5 of the recipient site Thickness 0.3 mm Cell Isolation Tissue digestion Dermoepidermal separation Step 2 Cell suspension Dermatome Local anesthesia (not supplied in the kit) Suspension in HA solution De-epithelialization Buffer solutions Hyaluronic Acid of the lesion by ablative laser or equivalent technique Step 3 Application of the Suspension deposit Drop by drop onto the recipient site cellular graft Dressing & bandage 1st layer Hydrophobic, 5-7 days Step 4 Postpoperative treatment Phototherapy Treatment Excimer lamp or UVB TL01, twice a week For 6 months starting one week after grafting Non-adhesive, hydrophobic dressing e.g. Mepitel®, Telfa Clear,Tegaderm® Petri Dish Container & Needles (1) Assessment of Non-cultured Autologous Epidermal Cell Grafting Resuspended in Hyaluronic Acid for Repigmenting Vitiligo and Piebaldism Lesions: A Randomized Clinical Trial. Bertolotti A, Leone G, Taïeb A, Soriano E, Pascal M, Maillard H, van Geel N. Acta Derm Venereol. 2021 Jul 30;101(7):adv00506. doi: 10.2340/00015555-3870. PMID: 34230975; PMCID: PMC9

Partnership Opportunities VitiCell® distribution EMEA/LATAM/ASPAC CUTISS AG 8 years, 55 FTE Zurich Personalized Bioengineered Tissue Therapy for Skin Surgery Private & public funding >125 M CHF Leading Innovation VITICELL® Positioning R&D Excellence Why partnering with us? CUTISS AG is leader in personalized, bio-engineered skin tissue therapies, with VitiCell® as a part of its pioneering product portfolio VITICELL® offers an advanced autologous grafting solution for cell-based skin re-pigmentation to treat stable vitiligo at point-of-care All-in-one kit Lasting benefit With a presence at Sophia-Antipolis,...